Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
SYN is in the long-term down -95% below S&P in 1 year.
Description: Synthetics Biologics, Inc., a biotechnology company, focuses on development of novel anti-infective biologics and drug candidates targeting specific pathogens that cause serious infections and other diseases. The company?s product candidates include Trimesta, which has completed phase II clinical trials for the treatment of relapsing-remitting multiple sclerosis and cognitive dysfunction in multiple sclerosis; SYN-010 that is in preclinical stage for the treatment of constipation-predominant irritable bowel syndrome; SYN-004, which is in preclinical stage for the treatment of clostridium difficile infection prevention; SYN-005 that is in preclinical stage for the treatment of pertussis; SYN-001, which is in discovery stage for the treatment of acinetobacter infection; and SYN-007 that is in discovery stage for the treatment of irritable bowel syndrome. It has a sublicense agreement with Meda AB for the development and commercialization of Effirma (flupirtine) for fibromyalgia in the United States, Canada, and
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||60.54%||Sales Growth - 4 Quarters||Sales Growth - Q/Q||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-206.36%||ROE||1741.78%||ROI|
|Current Ratio||0.89||Quick Ratio||Long Term Debt/Equity||Debt Ratio||-9.44|
|Gross Margin||Operating Margin||Net Profit Margin||Dividend Payout Ratio|
|Cash From Financing Activities||Cash From Investing Activities||Cash From Operating Activities||-20 K||Gross Profit|
|Net Profit||-5.46 M||Operating Profit||-8.21 M||Total Assets||13.72 M||Total Current Assets||13.62 M|
|Total Current Liabilities||15.34 M||Total Debt||Total Liabilities||15.34 M||Total Revenue|
|High 52 week||12.93||Low 52 week||0.32||Last close||0.58||Last change||-1.67%|
|RSI||25.15||Average true range||0.03||Beta||0.52||Volume||439.69 K|
|Simple moving average 20 days||-10.36%||Simple moving average 50 days||-12.21%||Simple moving average 200 days||-69.33%|
|Performance Week||-10.45%||Performance Month||-21.87%||Performance Quart||-13.12%||Performance Half||-37.14%|
|Performance Year||-95.22%||Performance Year-to-date||3.95%||Volatility daily||2.6%||Volatility weekly||5.81%|
|Volatility monthly||11.9%||Volatility yearly||41.24%||Relative Volume||277%||Average Volume||335.09 K|
|New High||New Low|
2019-05-24 10:25:44 | Sýn hf.: Notification of related party trading
2019-05-09 11:27:42 | Edited Transcript of SYN earnings conference call or presentation 8-May-19 8:30pm GMT
2019-05-08 18:02:45 | Synthetic Biologics: 1Q Earnings Snapshot
2019-02-28 02:58:59 | Edited Transcript of SYN earnings conference call or presentation 27-Feb-19 9:30pm GMT
2019-02-27 16:10:00 | Synthetic Biologics Reports 2018 Year End Operational Highlights and Financial Results
2019-02-27 15:05:03 | Sýn hf. : Q4 Investors presentation
2019-02-27 14:55:04 | Sýn hf. : Changes in management of Sýn hf.
2019-02-26 10:38:01 | Sýn hf. : Sýn finalizes the merger of Hey P/F with Nema P/F
2018-12-04 12:00:00 | Orchestra BioMed™ Appoints C. Evan Ballantyne as Chief Financial Officer
2018-11-27 08:20:00 | Report: Exploring Fundamental Drivers Behind Synthetic Biologics, Plexus, TG Therapeutics, Hortonworks, NorthWestern, and Archer Daniels Midland — New Horizons, Emerging Trends, and Upcoming Developments
2018-11-22 09:10:02 | New Trends in Healthcare Push Stocks Higher: 5 Picks
2018-11-21 09:25:00 | New Healthcare Trends Could Push Sector Stocks Higher
2018-11-09 01:17:04 | Edited Transcript of SYN earnings conference call or presentation 8-Nov-18 9:30pm GMT
2018-11-08 18:02:57 | Synthetic Biologics: 3Q Earnings Snapshot
2018-10-18 08:40:54 | Does Synthetic Biologics Inc NYSEMKT:SYN Have A High Beta?
2018-10-15 13:30:00 | Synthetic Biologics Announces Closing of $18,639,000 Public Offering
2018-10-12 07:35:00 | Factors of Influence in 2018, Key Indicators and Opportunity within Hyatt Hotels, E.W. Scripps, Cardtronics, Lincoln National, Synthetic Biologics, and Herc — New Research Emphasizes Economic Growth
2018-10-11 09:07:00 | Synthetic Biologics Prices $18,000,000 Public Offering
2018-09-30 09:26:06 | Who Are The Major Shareholders Of Synthetic Biologics Inc NYSEMKT:SYN?
2018-08-22 21:55:24 | Edited Transcript of SYN earnings conference call or presentation 8-Aug-18 8:30pm GMT
2018-08-17 14:32:59 | What Goes Through The Mind of A Trader When Taking A Position?
2018-08-13 07:55:00 | Consolidated Research: 2018 Summary Expectations for Fulton Financial, Leidos, Principal Financial Group, Quanta Services, Synthetic Biologics, and Sterling — Fundamental Analysis, Key Performance Indications
2018-08-08 17:31:53 | Synthetic Biologics: 2Q Earnings Snapshot
2018-08-08 14:30:00 | Synthetic Biologics, Inc. to Host Earnings Call
2018-08-08 12:27:48 | Is Now The Time To Bet On The Healthcare Sector And Synthetic Biologics Inc NYSEMKT:SYN?
2018-08-01 17:05:00 | Synthetic Biologics Announces Reverse Stock Split
2018-06-20 07:50:00 | Stock Performance Review on Sesen Bio and Three Other Biotech
2018-05-22 07:00:00 | Synthetic Biologics Announces Acceptance of Compliance Plan by NYSE American
2018-05-21 07:25:00 | Stock Performance Review on Tesaro and Three Other Biotech Industry
2018-05-14 07:40:00 | Report: Developing Opportunities within Crown, American Equity Investment Life Holding, Acco Brands, Synthetic Biologics, Universal Display, and Lamb Weston — Future Expectations, Projections Moving into 2018
2018-05-09 05:11:09 | Synthetic Biologics: 1Q Earnings Snapshot
2018-05-08 19:46:01 | Edited Transcript of SYN earnings conference call or presentation 8-May-18 8:30pm GMT
2018-03-09 08:25:00 | Report: Exploring Fundamental Drivers Behind EOG Resources, Alteryx, Synthetic Biologics, Extreme Networks, Knight-Swift Transportation Holdings Inc., and Select Medical — New Horizons, Emerging Trends, and Upcoming Developments